Merit Financial Group LLC grew its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 59.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 6,845 shares of the medical research company's stock after purchasing an additional 2,552 shares during the period. Merit Financial Group LLC's holdings in IQVIA were worth $1,207,000 as of its most recent SEC filing.
A number of other hedge funds also recently made changes to their positions in IQV. JPMorgan Chase & Co. boosted its position in IQVIA by 46.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Brighton Jones LLC lifted its holdings in IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company's stock worth $703,000 after purchasing an additional 2,537 shares during the period. Spire Wealth Management increased its stake in IQVIA by 42.9% during the 4th quarter. Spire Wealth Management now owns 733 shares of the medical research company's stock valued at $144,000 after buying an additional 220 shares during the period. Bleakley Financial Group LLC raised its position in shares of IQVIA by 40.7% during the 4th quarter. Bleakley Financial Group LLC now owns 7,881 shares of the medical research company's stock worth $1,549,000 after buying an additional 2,281 shares in the last quarter. Finally, Silver Oak Securities Incorporated lifted its stake in shares of IQVIA by 18.0% in the 4th quarter. Silver Oak Securities Incorporated now owns 2,380 shares of the medical research company's stock worth $470,000 after acquiring an additional 363 shares during the period. Institutional investors own 89.62% of the company's stock.
IQVIA Price Performance
Shares of NYSE:IQV traded up $1.83 on Monday, hitting $154.15. The stock had a trading volume of 2,410,372 shares, compared to its average volume of 1,603,194. The firm's 50 day moving average price is $147.69 and its 200-day moving average price is $178.90. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $252.88. The company has a market capitalization of $26.67 billion, a price-to-earnings ratio of 20.55, a price-to-earnings-growth ratio of 1.99 and a beta of 1.28.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The firm had revenue of $3.83 billion for the quarter, compared to analyst estimates of $3.77 billion. During the same period in the previous year, the business earned $2.54 earnings per share. The company's revenue for the quarter was up 2.5% compared to the same quarter last year. On average, equities research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
Analyst Ratings Changes
A number of brokerages recently weighed in on IQV. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and reduced their target price for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Hsbc Global Res downgraded IQVIA from a "strong-buy" rating to a "hold" rating in a research note on Friday, April 25th. Morgan Stanley boosted their target price on IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Truist Financial lowered their price target on IQVIA from $263.00 to $216.00 and set a "buy" rating on the stock in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. cut their price target on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a report on Monday, May 19th. Eight investment analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $226.32.
Get Our Latest Research Report on IQV
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
